JP2012527444A5 - - Google Patents

Download PDF

Info

Publication number
JP2012527444A5
JP2012527444A5 JP2012511367A JP2012511367A JP2012527444A5 JP 2012527444 A5 JP2012527444 A5 JP 2012527444A5 JP 2012511367 A JP2012511367 A JP 2012511367A JP 2012511367 A JP2012511367 A JP 2012511367A JP 2012527444 A5 JP2012527444 A5 JP 2012527444A5
Authority
JP
Japan
Prior art keywords
subject
compound according
mir
compound
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012511367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012527444A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/001384 external-priority patent/WO2010133970A1/en
Publication of JP2012527444A publication Critical patent/JP2012527444A/ja
Publication of JP2012527444A5 publication Critical patent/JP2012527444A5/ja
Pending legal-status Critical Current

Links

JP2012511367A 2009-05-20 2010-05-19 代謝障害に関するターゲッティングマイクロrna Pending JP2012527444A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18002409P 2009-05-20 2009-05-20
US61/180,024 2009-05-20
US32287810P 2010-04-11 2010-04-11
US61/322,878 2010-04-11
PCT/IB2010/001384 WO2010133970A1 (en) 2009-05-20 2010-05-19 Targeting micrornas for metabolic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015222848A Division JP6300775B2 (ja) 2009-05-20 2015-11-13 代謝障害に関するターゲッティングマイクロrna

Publications (2)

Publication Number Publication Date
JP2012527444A JP2012527444A (ja) 2012-11-08
JP2012527444A5 true JP2012527444A5 (https=) 2013-07-04

Family

ID=42563091

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012511367A Pending JP2012527444A (ja) 2009-05-20 2010-05-19 代謝障害に関するターゲッティングマイクロrna
JP2015222848A Expired - Fee Related JP6300775B2 (ja) 2009-05-20 2015-11-13 代謝障害に関するターゲッティングマイクロrna

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015222848A Expired - Fee Related JP6300775B2 (ja) 2009-05-20 2015-11-13 代謝障害に関するターゲッティングマイクロrna

Country Status (7)

Country Link
US (6) US8592388B2 (https=)
EP (1) EP2432880A1 (https=)
JP (2) JP2012527444A (https=)
CN (2) CN102459598B (https=)
AU (2) AU2010250838B2 (https=)
CA (1) CA2763016C (https=)
WO (1) WO2010133970A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2763016C (en) 2009-05-20 2018-04-17 Eth Zurich Targeting micrornas for metabolic disorders
EP2608812B1 (en) * 2010-08-25 2018-08-15 The General Hospital Corporation Nucleic acids targeting mir-33 micrornas for regulating lipid metabolism
CA2819378A1 (en) 2010-12-02 2012-06-07 Katholieke Universiteit Leuven, K.U.Leuven R&D Irak-related interventions and diagnosis
WO2012145374A1 (en) * 2011-04-19 2012-10-26 Regulus Therapeutics Inc. TARGETING miR-378 FAMILY MEMBERS FOR THE TREATMENT OF METABOLIC DISORDERS
WO2012174470A1 (en) * 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of pyruvate carboxylase expression
WO2013188879A1 (en) 2012-06-16 2013-12-19 Atherotech, Inc. Measurement of serum lipoproteins
EP2908853B1 (en) * 2012-10-21 2018-12-05 University Of Rochester Thy1 (cd90) as a therapy to control adipose tissue accumulation
US20160145612A1 (en) 2013-03-06 2016-05-26 Royal College Of Surgeons In Ireland Diagnosis and treatment of metabolic disorders
WO2014150772A1 (en) * 2013-03-15 2014-09-25 The Johns Hopkins University Methods for treating or preventing fatty liver disease using ctrp3
US9976140B2 (en) 2013-06-14 2018-05-22 Joslin Diabetes Center, Inc. Microrna and uses in brown fat differentiation
KR102515248B1 (ko) 2013-11-22 2023-03-29 사브레 테라퓨틱스 엘엘씨 오토탁신 억제제 화합물
DK3110973T3 (da) 2014-02-27 2019-05-13 Univ Leuven Kath Oxidativt stress og kardiovaskulære sygdomshændelser
US10704097B2 (en) 2014-02-27 2020-07-07 Katholieke Universiteit Leuven Oxidative stress and cardiovascular disease events
CN103940998B (zh) * 2014-05-04 2016-04-20 山东大学 血清microRNA作为肝细胞癌转移的早期诊断标志物的应用
TW201613949A (en) 2014-08-07 2016-04-16 Regulus Therapeutics Inc Targeting microRNAs for metabolic disorders
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
CN105457028B (zh) * 2014-09-04 2019-08-20 中国科学院上海生命科学研究院 在骨形成中发挥调控作用的应力敏感性microRNA
MX2017015225A (es) 2015-05-27 2018-02-19 Pharmakea Inc Inhibidores de la autotaxina y sus usos.
EP3303629A1 (en) * 2015-06-05 2018-04-11 Regulus Therapeutics Inc. Non-alcoholic fatty liver disease biomarkers
US10844383B1 (en) 2019-09-18 2020-11-24 Dasman Diabetes Institute Microrna dyslipidemia inhibitor
CN112635018B (zh) * 2020-12-24 2025-04-18 江苏精策医疗科技有限公司 一种提高无创血糖代谢热整合法检测的准确性的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1340514A (zh) * 2000-08-31 2002-03-20 上海博德基因开发有限公司 一种新的多肽——人U4/U6核内小RNA结合蛋白(U4/U6 sn RNP)13.09和编码这种多肽的多核苷酸
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
FR2863640B1 (fr) * 2003-12-16 2006-04-07 Sinnoveg Dispositif de haie defensive vegetale anti-intrusion et son procede de realisation
US20050261233A1 (en) * 2004-04-21 2005-11-24 Sanjay Bhanot Modulation of glucose-6-phosphatase translocase expression
EP2290071B1 (en) 2004-05-28 2014-12-31 Asuragen, Inc. Methods and compositions involving microRNA
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
EP1984499B1 (en) 2006-01-27 2015-05-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
CA2648132C (en) 2006-04-03 2019-05-28 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP3192788A1 (en) 2006-10-03 2017-07-19 Arbutus Biopharma Corporation Lipid containing formulations
EP2623599B1 (en) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
CA2763016C (en) * 2009-05-20 2018-04-17 Eth Zurich Targeting micrornas for metabolic disorders

Similar Documents

Publication Publication Date Title
JP2012527444A5 (https=)
JP2012050439A5 (https=)
JP2009506124A5 (https=)
RU2501803C2 (ru) Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4)
JP2012050438A5 (https=)
Van Rooij et al. Toward microrna–based therapeutics for heart disease: The sense in antisense
JOP20200202A1 (ar) اجسام مضادة بشرية لمستقبل الجلوكاجون
JP2012029693A5 (https=)
JP2010512747A5 (https=)
JP2013518605A5 (https=)
JP2015502365A5 (https=)
WO2010023327A4 (en) Method for obtaining oligonucleotide aptamers and uses thereof
JP2017509354A5 (https=)
JP2016506240A5 (https=)
IL300119A (en) Oligonucleotides to induce paternal UBE3A expression
WO2009148605A3 (en) Methods for treating hypercholesterolemia
JP2010535786A5 (https=)
RU2016115782A (ru) Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 и транскрипционному фактору е3 (tfe3)
JP2019500428A5 (https=)
JP2012516856A5 (https=)
JP2014503192A5 (https=)
JP2015520170A5 (https=)
WO2010018950A3 (en) Protein scaffold library based on kringle domain structure and uses thereof
JP2014504857A5 (https=)
JP2016520310A5 (https=)